Pharming (PHAR) Non Operating Investment Income (2019 - 2024)
Pharming's (PHAR) quarterly Non Operating Investment Income came in at -$0.2 in Q4 2024, down 100.0% YoY from $930000.0 in Q1 2024, and down 100.0% on a QoQ basis from $21000.0 in Q3 2024.
Pharming (PHAR) Non Operating Investment Income (2019 - 2024) Analysis & Trends
Pharming (PHAR) has 6 years of Non Operating Investment Income data on file, last reported at -$0.2 in Q4 2024.
- Quarterly Non Operating Investment Income fell 100.0% year-over-year to -$0.2 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $6.1 million (up 2030.99% YoY) and the FY2025 annual result came in at $2.3 million, down 53.01% from the prior year.
- Non Operating Investment Income fell to -$0.2 in Q4 2024, from $21000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $5.1 million in Q2 2024 to a low of -$1.2 million in Q4 2022.
- A 5-year average of $536336.8 and a median of -$0.2 in 2024 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income slumped 3900.0% — and 2023, when it soared 177.5%.
- Tracing PHAR's Non Operating Investment Income over 5 years: stood at -$71537.4 in 2020, then jumped by 58.06% to -$30000.0 in 2021, then tumbled by 3900.0% to -$1.2 million in 2022, then soared by 177.5% to $930000.0 in 2023, then slumped by 100.0% to -$0.2 in 2024.
- The last three Non Operating Investment Income figures came in at -$0.2 (Q4 2024), $21000.0 (Q3 2024), and $5.1 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.20 |
| Dec 31, 2024 | -0.20 |
| Sep 30, 2024 | 21,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 5.14 Mn |
| Jun 30, 2024 | 5.14 Mn |
| Dec 31, 2023 | 930,000.00 |
| Dec 31, 2023 | 930,000.00 |
| Dec 31, 2022 | -1.20 Mn |
| Dec 31, 2022 | -1.20 Mn |
| Dec 31, 2021 | -30,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | -15,330.74 |
| Sep 30, 2021 | -15,330.74 |
| Dec 31, 2020 | -71,537.39 |
| Dec 31, 2020 | -71,537.39 |
| Sep 30, 2020 | 54,899.63 |
| Sep 30, 2020 | 54,899.63 |
| Dec 31, 2019 | 231,339.52 |
| Dec 31, 2019 | 231,339.52 |